2023
Repeat Ivermectin Mass Drug Administrations for Malaria Control II: Protocol for a Double-blind, Cluster-Randomized, Placebo-Controlled Trial for the Integrated Control of Malaria
Foy B, Some A, Magalhaes T, Gray L, Rao S, Sougue E, Jackson C, Kittelson J, Slater H, Bousema T, Da O, Coulidiaty A, Colt M, Wade M, Richards K, Some A, Dabire R, Parikh S. Repeat Ivermectin Mass Drug Administrations for Malaria Control II: Protocol for a Double-blind, Cluster-Randomized, Placebo-Controlled Trial for the Integrated Control of Malaria. JMIR Research Protocols 2023, 12: e41197. PMID: 36939832, PMCID: PMC10132043, DOI: 10.2196/41197.Peer-Reviewed Original ResearchIvermectin mass drug administrationMass drug administrationINTERNATIONAL REGISTERED REPORT IDENTIFIERMalaria incidenceDrug AdministrationMalaria transmissionIntense seasonal malaria transmissionMalaria controlSecondary safety outcomesParallel-group trialSeasonal malaria transmissionAdverse event monitoringActive case surveillancePrimary outcomeControl IINonpregnant individualsPostintervention changesTrial interventionCare interventionsSafety outcomesCluster RandomizedSubset of individualsCase surveillanceConsecutive daysEntomological assessments
2015
The epidemiological impact of HIV antiretroviral therapy on malaria in children
Greenhalgh S, Ndeffo M, Galvani AP, Parikh S. The epidemiological impact of HIV antiretroviral therapy on malaria in children. AIDS 2015, 29: 473-482. PMID: 25486414, PMCID: PMC4391884, DOI: 10.1097/qad.0000000000000550.Peer-Reviewed Original ResearchConceptsHIV protease inhibitorsRecurrent malariaMalaria transmissionAntiretroviral therapyArtemether-lumefantrineAnnual incidenceProtease inhibitorsFirst-line antiretroviral regimenFirst-line antiretroviral therapyArtemether-lumefantrine treatmentHIV-negative childrenFirst-line antimalarialsHIV prevalence settingsHIV antiretroviral therapyRecent clinical trialsHIV prevalence levelsMalaria transmission settingsMalaria transmission intensityAntiretroviral regimenAntimalarial treatmentHIV prevalenceProphylactic effectPrevalence settingsClinical trialsHealth burden